Lower costs through TrumpRX may allow more people to access FDA-approved, safe GLP-1 medications, reducing reliance on compounded alternatives, which can carry legal and safety risks
The results are in line with an earlier study by these same authors [12]
They have not been formally established for retatrutide because retatrutide is not yet FDA approved, and clinical trial protocols handle missed doses through site-specific procedures rather than published guidance
With one in eight Americans using GLP-1 drugs by 2025, these shifts are likely to continue affecting both farmers and the broader food industry in significant ways
Your provider can evaluate whether compounded semaglutide, tirzepatide, or other GLP-1 agents align with your health profile and treatment goals
Williams, MD , clinical assistant professor in the Department of Ophthalmology at NYU Grossman School of Medicine, says its important to note that no current study shows direct causation between GLP-1 use and NAION only an association